Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD
 

Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France

What kind of specific, actionable information is contained on an NGS CGP report? In what context is hybrid capture-based NGS especially valuable at the front lines of precision cancer care? Video

What kind of specific, actionable information is contained on an NGS CGP report? In what context is hybrid capture-based NGS especially valuable at the front lines of precision cancer care?

What kind of specific, actionable information is contained on an NGS CGP report? In what context is hybrid capture-based NGS especially valuable at the front lines of precision cancer care?
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples? Video

There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?

There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy? Video

Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?

Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Using the FoundationOne Report as an example, can you explain what should appear on an NGS report and what interpretative dimensions are necessary to optimize its clinical value as treatment roadmap? Video

Using the FoundationOne Report as an example, can you explain what should appear on an NGS report and what interpretative dimensions are necessary to optimize its clinical value as treatment roadmap?

Using the FoundationOne Report as an example, can you explain what information should ideally appear on an NGS report and what interpretative dimensions of the report are necessary to optimize its clinical value as treatment roadmap?
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD